Nanoscope Therapeutics Inc. today announced that clinical development of its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in two presentations at the 22nd Euretina Congress, taking place September 1-4, 2022, in Hamburg, Germany and online.
August 29, 2022
· 2 min read